[
  {
    "ts": "2026-02-20T13:08:23+00:00",
    "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
    "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
    "url": "https://finance.yahoo.com/news/barclays-launches-u-biopharma-coverage-130823921.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "5ba041e7-1a78-33cf-944e-d7c09e3eea86",
      "content": {
        "id": "5ba041e7-1a78-33cf-944e-d7c09e3eea86",
        "contentType": "STORY",
        "title": "Barclays launches U.S. biopharma coverage with four preferred picks",
        "description": "",
        "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
        "pubDate": "2026-02-20T13:08:23Z",
        "displayTime": "2026-02-20T13:08:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/barclays-launches-u-biopharma-coverage-130823921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/barclays-launches-u-biopharma-coverage-130823921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T12:59:29+00:00",
    "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street’s expectations, and the stock was down from the opening bell to the close. All ... Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
    "url": "https://247wallst.com/investing/2026/02/20/here-are-fridays-top-wall-street-analyst-research-calls-amgen-etsy-eldorado-gold-ge-aerospace-merck-southern-company-walmart-yeti-and-more/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "090a909e-bc81-36d6-91e8-6b4ce7526b98",
      "content": {
        "id": "090a909e-bc81-36d6-91e8-6b4ce7526b98",
        "contentType": "STORY",
        "title": "Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
        "description": "",
        "summary": "Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street’s expectations, and the stock was down from the opening bell to the close. All ... Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
        "pubDate": "2026-02-20T12:59:29Z",
        "displayTime": "2026-02-20T12:59:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/68a116ecb9011f71579b3c32cd49343b",
          "originalWidth": 1366,
          "originalHeight": 767,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rYIxCrA6AKDxNsz2Qsl7cA--~B/aD03Njc7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/68a116ecb9011f71579b3c32cd49343b.cf.webp",
              "width": 1366,
              "height": 767,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iZWmPqjiX4v_sd4A3P5Kcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/68a116ecb9011f71579b3c32cd49343b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/20/here-are-fridays-top-wall-street-analyst-research-calls-amgen-etsy-eldorado-gold-ge-aerospace-merck-southern-company-walmart-yeti-and-more/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/friday-top-wall-street-analyst-125929009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "ETSY"
            },
            {
              "symbol": "EGO"
            },
            {
              "symbol": "GE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SO"
            },
            {
              "symbol": "PAY"
            },
            {
              "symbol": "RS"
            },
            {
              "symbol": "BWA"
            },
            {
              "symbol": "CDE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "SOMN"
            },
            {
              "symbol": "YETI"
            },
            {
              "symbol": "AFRM"
            },
            {
              "symbol": "GPI"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T08:00:00+00:00",
    "headline": "No one-trick pony in oncology, Merck’s cancer footprint is expanding",
    "summary": "The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.",
    "url": "https://www.pharmavoice.com/news/merck-oncology-cancer-drug-keytruda-adc-daiichi/812651/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "ba42772f-acc7-3cc7-8e7e-cebb631bd694",
      "content": {
        "id": "ba42772f-acc7-3cc7-8e7e-cebb631bd694",
        "contentType": "STORY",
        "title": "No one-trick pony in oncology, Merck’s cancer footprint is expanding",
        "description": "",
        "summary": "The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.",
        "pubDate": "2026-02-20T08:00:00Z",
        "displayTime": "2026-02-20T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/4f02aadde182e9baff9817168d7bfc06",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A Merck sign hangs on the side of an office building in South San Francisco, California.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k1Yu5D9shN.GN7A9Dy6UZQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/4f02aadde182e9baff9817168d7bfc06.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K3EGoMpFIKlQnk5fyDpURQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/4f02aadde182e9baff9817168d7bfc06.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/merck-oncology-cancer-drug-keytruda-adc-daiichi/812651/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/no-one-trick-pony-oncology-080000747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T17:05:00+00:00",
    "headline": "Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?",
    "summary": "BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.",
    "url": "https://finance.yahoo.com/news/merck-vs-bristol-myers-pharma-170500212.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e15b539d-ed2b-3142-8d82-813c5b484258",
      "content": {
        "id": "e15b539d-ed2b-3142-8d82-813c5b484258",
        "contentType": "STORY",
        "title": "Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?",
        "description": "",
        "summary": "BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.",
        "pubDate": "2026-02-20T17:05:00Z",
        "displayTime": "2026-02-20T17:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NuaC8R_wAbhCY5KPvmp9LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cLIW4zpH3bXqWfT.Oe9Uew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-vs-bristol-myers-pharma-170500212.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-vs-bristol-myers-pharma-170500212.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T23:31:10+00:00",
    "headline": "Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 16 Best Dividend Stocks with Rising Payouts. On February 13, Deutsche Bank analyst James Shin upgraded Merck & Co., Inc. (NYSE:MRK) to Buy from Hold. The analyst raised his price target on the stock to $150 from $115. In a research note, he said the market […]",
    "url": "https://finance.yahoo.com/news/deutsche-bank-upgrades-merck-mrk-233110730.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "60542dac-ebcb-3316-8ff8-a444d0177aec",
      "content": {
        "id": "60542dac-ebcb-3316-8ff8-a444d0177aec",
        "contentType": "STORY",
        "title": "Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 16 Best Dividend Stocks with Rising Payouts. On February 13, Deutsche Bank analyst James Shin upgraded Merck & Co., Inc. (NYSE:MRK) to Buy from Hold. The analyst raised his price target on the stock to $150 from $115. In a research note, he said the market […]",
        "pubDate": "2026-02-20T23:31:10Z",
        "displayTime": "2026-02-20T23:31:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/deutsche-bank-upgrades-merck-mrk-233110730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/deutsche-bank-upgrades-merck-mrk-233110730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]